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Fracture healing has been shown to be dependent on the inflammatory cascade1-4.  
Prostaglandins appear to have a particularly important role2.  Several studies have looked 
at cyclo-oxygenase-1 (COX-1) and cyclo-oxygense-2 (COX-2) knockout mice and 
identified impaired fracture healing specifically in the COX-2 knockout mice1,2. 
It has been hypothesized that based on this association between the COX-2 
knockout animal models and impaired fracture healing, there could be a potentially 
negative impact on fracture healing with the concurrent use of non-steroidal anti-
inflammatory drugs (NSAID) for analgesia use due to their impact on the COX-1 & 
COX-2 enzymes.  Several animal models have produced results that show impaired 
fracture healing with the use of various NSAID medications1,5. 
NSAID medications are among the most commonly used analgesic medications 
world wide, and it was estimated in 2010 (updated 2015 data is expected to be published 
next year) that about 29 million adults in the United States regularly used NSAID 
medications at least three times per week for more than three months6. This was an 
increase of 41% from 2005 data6. 
Other analgesic options in fracture healing include acetaminophen, tramadol and 
opiates.  Acetaminophen’s main limitation is with hepatic disease.  However, opiates are 
widely known throughout the medical community as well as the general public regarding 
the epidemic of abuse.  In 2012, there were 259 million opiate prescriptions in the United 
States7.  This is enough to provide each adult one bottle of medication7. 
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In 2015, 20.5 million Americans over the age of 12 had a diagnosis of substance 
use disorder7.   Of which, 2 million were related to prescription medications, including 
opiates, and almost 600,000 were related to heroin7.  It is estimated that 4 out of 5 heroin 
users started by using prescription medications7.  There were 20,000 lethal drug 
overdoses related prescription drugs and almost 13,000 related to heroin7.  It is evident 
that medical providers have an integral role in reducing the number of opiate 
prescriptions through the use of alternative analgesic options. 
The aim of this paper is to review the current literature on the potential risk 
between NSAID medication use in humans and the risk of non- or mal-union following 
acute fracture.  It is important to have adequate evidence if we are to exclude the use of 
NSAID medications for their analgesic properties as that would likely increase the 
number of opiate prescriptions, which has obvious impacts on the current opiate 
epidemic.  It is also an important topic as NSAID medications are a widely used over the 
counter analgesic option and therefore potentially an important educational topic between 
medical providers and their patients with fracture if there is found to be an increased risk 





A retrospective case-control database review by Hernandez et al.8 looked at 20 
years worth of patient data (563 cases and 2,252 controls, n=2815)8.  They found that the 
use of NSAID medications within 12 months prior to fracture increased the odds 
developing non- or mal-union as well as delayed union (adjusted OR 2.5, 95% CI: 2.0-
3.2)8 (Appendix Figure 1). 
A retrospective cohort of 9.995 Medicare patients in the United States by 
Bhattacharyya et al.9 looked at both NSAID medication and opiate exposure over 90 days 
post humeral shaft fracture.  These findings showed that both NSAID medication and 
opiate exposure between days 0-30 and days 31-60 did not increase the risk of non-
union9.  It wasn’t until days 61-90 that exposure to either medication increased the risk of 
nonunion (NSAID: RR 3.9, 95% CI 2.0-6.2; opiate: RR 2.7, 95% CI 1.5-5.2)9 (Appendix 
Figure 2). 
A randomized, double-blind, clinical trial by Drendel et al.10 followed 244 
pediatric patients with an arm fracture for up to 4 years and looked at ibuprofen and 
acetaminophen with codeine as analgesic options and the risk of nonunion or refracture at 
the same site.  They identified 4 patients (1.6%) with refracture, of which 3 were treated 
with acetaminophen and 1 was treated with ibuprofen10.  They did not identify any 
fracture nonunions in their study10. 
A retrospective study by Jeffcoach et al.11 looked at NSAID medication use 
among long-bone fractures undergoing operative treatment (n=1,901; 42.1% femur, 23% 
tibia, and/or 22.5% humerus) and the risk for non- or mal-union.  They identified 60 
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patients (3.2%) with non- or mal-union and found that those receiving an NSAID 
medication (mainly ibuprofen and ketorolac) during the inpatient postoperative setting 
were more likely to have a complication (OR 2.17; 95% CI 1.15-4.1; p < 0.016)11 
(Appendix Figure 3). 
A retrospective study by Giannoudis et al.12 compared 32 patients with diaphyseal 
fracture of the femur resulting in nonunion or appropriately healed fractures.  They 
identified NSAID medication use (mainly ibuprofen and diclofenac), especially for 
longer than four weeks, as a predictor of increased odds of non-union (OR 10.74; 95% CI 
3.55-33.23)12 (Appendix Figure 4). 
A randomized double-blind placebo controlled trial by Adolphson et al.13 looked 
at 42 postmenopausal women with displaced Colles’ fracture and whether the use of 
NSAID medication (peroxicam) for 8 weeks affected the rate of recovery.  They used 
radiographic examinations to measure bone mineral content and found no significant 
difference between those treated with NSAID medication versus those treated with 
placebo13. 
A randomized double-blind trial by Davis et al.14 in 1988 looked at 100 Colles’ 
fractures treated with NSAID medication (flurbiprofen 50 mg TID) versus placebo.  They 
found no difference in rates of non- or mal-union between the two groups14. 
A retrospective case-controlled study by Chuang et al.15 followed patients from 
Taiwan who underwent hip fracture surgery over a 15 year time period and their risk for a 
second hip fracture.  They concluded that the higher the mean daily dose (p = 0.003) as 
well as the longer time course (p < 0.001) of treatment with NSAID medications 
(ibuprofen, diclofenac, celecoxib) was associated with an increased risk of sustaining a 
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second hip fracture15.   This study also found similar results when looking at paracetamol 





The research topic presented here was conducted using a search of the PubMed 
database throughout the month of May 2017.  The key search words utilized were: 
NSAID, non-steroidal anti-inflammatory drugs, fracture, non-union and mal-union.  The 
goal of this particular study was to analyze human data regarding the use of NSAID 
medications following acute fracture and the potential risk of non- or mal-union.  It was 
quickly noted that there is an overall lack of human clinical trials looking at this potential 
issue.  Therefore, other review articles on the topic were reviewed as well for sources not 
identified through the above listed search methods to ensure adequate volume of material 





Data looking at the effects of the inflammatory process on osteoblasts and 
osteoclasts indicate a positive impact that prostaglandins have on promoting 
osteogenesis1-5.  However, human data is conflicting as noticed in the 8 human studies 
reviewed here – 3 studies found no statistically significant risk between NSAID 
medications and non- or mal-union10,13,14, while 5 studies found statistically significant 
risks8,9,11,12,15.  However, review, analysis and discussion of the data is necessary before a 
final conclusion can be made. 
Most of these studies were conducted in a retrospective manner, which has many 
potential biases, namely the difficulty in predicting a cause and effect mechanism through 
this manner.  The study conducted by Bhattacharyya et al.9 had the largest number of 
subjects and they interestingly looked at specific time periods for NSAID medication use 
following acute fracture.  With this interesting viewpoint, they identified that patients 
utilizing either NSAID medications or opiates for up to 3 months had a significant risk 
for non- or mal-union whereas either NSAID medications or opiates used for less than 2 
months had no statistically significant risk.  The authors of this study bring up an 
excellent question with this data in mind: could the data for the risk of NSAID 
medications and non- or mal-union reported in other studies simply be secondary to the 
pain associated with non- or mal-union necessitating increased use of analgesic options?  
This certainly seems plausible when considering that there is no known pharmacologic 
mechanism for opiates directly inhibiting osteogenesis. 
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With the results of Bhattacharyya et al.9 in mind, it is also helpful to consider the 
15-year study presented by Chuang et al.15  In their retrospective look at various 
medication exposures on the occurrence of a second hip fracture (although this is not a 
non- or mal-union, this is still helpful to answer the question posed for this research topic 
as a second fracture can be considered a marker for osteogenesis), the authors stated that 
NSAID medications do present a significant risk for a second hip fracture in both their 
abstract and well as conclusion statements.  However, upon careful review of the data, it 
should be noted that paracetamol was also associated with a significant risk for a second 
hip fracture.  Interestingly, the authors did not mention this important finding in their 
discussion nor their conclusion.  Similar to opiates, paracetamol does not have a known 
pharmacologic mechanism that would inhibit osteogenesis.  This strengthens the 
argument by Bhattacharyya et al.9 that the association identified between NSAID 
medications and non- or mal-union could be secondary to increased pain from non- or 
mal-union necessitating analgesic therapy. Also of note, the conclusion by Chuang et al.15 
stating that NSAID medications as a whole have an impact on the risk for a second hip 
fracture was only true for diclofenac, ibuprofen and celecoxib.  Naproxen, etodolac and 
rofecoxib were not found to have a statistically significant impact.  Therefore the authors 
came to a drastic conclusion that is not fully supported by their data. 
The results from Giannoudis et al.12 also retrospectively found a statistically 
significant risk between NSAID medication use and non-union when used for greater 
than four weeks.  Considering the combination of this study along with those from 
Bhattacharyya et al.9 and Chuang et al.15, there seems to be a potential protopathic bias 
between NSAID medication exposure and non- or mal-union.  In discussing analgesic 
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pharmacotherapy with multiple orthopedic providers, the general consensus is the need 
for analgesic pharmacotherapy for at most a few weeks.  Therefore the prolonged 
analgesic pharmacotherapy courses seen in the studies by Bhattacharyya et al.9 and 
Giannoudis et al.12 are not typically experienced in general orthopedic practice. 
Another interesting question to consider following these results from 
Bhattacharyya et al.9 and Giannoudis et al.12 would be the impact that proper fracture 
immobilization would have on long-term analgesic therapy needs.  This would seem to be 
a likely association considering the role that proper fracture immobilization has on pain 
levels, however, a PubMed search including fracture, immobilization, pain and analgesic 
did not identify any specific studies looking at the potential association between proper 
immobilization and long-term analgesic therapy needs. 
The results published by Hernandez et al.8 are an interesting way to look at the 
potential risks that NSAID medications may have on non- or mal-union.  Their study’s 
design was able to identify risk factors for non- or mal-union before the fracture ever 
occurred.  This does strengthen the mechanistic, in vivo and animal model studies that 
point towards a risk for NSAID medication use and non- or mal-union.  This is a very 
important variable considering the previously mentioned data from 2010 on the 
frequency of regular NSAID medication use among the United States population. 
The results from Jeffcoach et al.11 found a risk between NSAID medication and 
fracture complications (non- or mal-union, and infection) when exposure to NSAID 
medication occurred acutely in the inpatient setting following fracture onset.  This does 
add strength to the data from Hernadez et al.8 regarding NSAID medication exposure 
before fracture ever occurred.  It seems plausible mechanistically that perhaps 
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osteogenesis occurring in normal day-to-day life is negatively impacted by NSAID 
medications and therefore could decrease overall bone mineral density, which in turn 
could lead to fracture complications.  However, a PubMed search including NSAID, non-
steroidal anti-inflammatory drugs, osteoporosis and bone mineral density did not result in 
any studies reporting on this potential impact.  Therefore, future studies are warranted to 
look into this potential mechanism.  Another question that could be raised related to this 
search would be a potential association between chronic pain condition and reduced bone 
mineral density.  Similarly, a PubMed search including chronic pain, bone mineral 
density and osteoporosis did not result in any studies reporting on this potential impact.  
This was discussed with an endocrinologist who was not aware of any data pertaining to 





Non- and mal-union following acute fracture has numerous impacts on quality of 
life and social issues (work productivity, family dynamics, etc.).  Healthcare providers 
have an important role in assessing and managing various risks to decrease potential 
morbidity involved.  The research question presented here, looking at NSAID 
medications as a possible risk factor for non- or mal-union, is an important topic for 
multiple reasons.  First, NSAID medications are widely used both through prescriptions, 
and arguably more importantly over-the-counter.  Secondly, if NSAID medications are to 
be avoided as an analgesic option following acute fracture, healthcare providers must 
utilize other analgesic options that have their own associated morbidity and mortality, 
namely the opiate epidemic. 
NSAID medication use appears to have a mechanistic in-vivo and in-vitro animal 
risk for the development of non- and mal-union following fracture.  However, human 
data is lacking to support total avoidance of this analgesic option for all patients.  Based 
on the current literature review presented above, I recommend acetaminophen as first line 
analgesic therapy following acute fracture.  Acetaminophen should be titrated as needed 
for pain control to the age-adjusted maximum recommended dose (ie. 4 grams per day for 
adults and 3 grams per day for geriatrics) before alternative analgesic options are 
introduced. 
I recommend NSAID medications as second line analgesic therapy after 
reviewing pertinent patient comorbid conditions.  Considering the mechanistic in-vivo 
and in-vitro animal data, it is recommended to avoid NSAID medication therapy in those 
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with reduced bone mineral density risk factors including, but not limited to, endocrine 
disorders such as osteoporosis, hyperparathyroidism, hypercortisolism and 
hyperthyroidism; rheumatologic disorders requiring high-dose or long-term 
glucocorticoid therapy such rheumatoid arthritis, gout, and lupus; oncologic disorders 
such as multiple myeloma and bone related cancers; and gastrointestinal esophageal 
reflux disease with high-dose or long-term proton-pump inhibitor therapy.  Other obvious 
limitations to NSAID medication therapy aside from reduced bone mineral density 
include cardiovascular, gastrointestinal ulcer and renal conditions.  If co-morbid 
conditions are identified, I recommend tramadol or other opiates as second-line analgesic 
therapy.  However, if co-morbid conditions that could negatively impact bone mineral 
density are ruled out, NSAID medications should be utilized as second-line analgesic 
therapy and titrated as needed for pain control to their respective pain dosing regimens 
(ie. ibuprofen 2400 mg or naproxen 1250 mg per day) before consideration of tramadol 
or other opiates as a third-line analgesic therapy. 
Obviously, attention should also be given towards appropriate immobilization of 
acute fractures to aid in minimizing the risk of developing non- or mal-union issues.  In 
discussion with several orthopedic providers, it was identified that appropriate 
immobilization of acute fractures is a primary means of reducing pain.  It would be 
reasonable to identify patients that are requiring prolonged analgesic therapy for longer 
than three weeks as having potentially improper immobilization of the fracture and 
therefore need appropriate interventions. 
Obviously, there is a need for future, well-designed studies that look prospectively at 
NSAID medication exposure following acute fracture and the risk of non- or mal-union 
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issues.   Other identified areas in need of research include potential associations between 
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